home / stock / akro / akro quote
Last: | $ |
---|---|
Change Percent: | -7.69% |
Open: | $27.10 |
Close: | $24.97 |
High: | $27.10 |
Low: | $24.64 |
Volume: | 89,888 |
Last Trade Date Time: | 02/12/2020 04:42:16 pm |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$ | $27.10 | $24.97 | $27.10 | $24.64 | 89,888 | 02-12-2020 |
$ | $27.08 | $27.05 | $27.27 | $26.50 | 98,425 | 02-11-2020 |
$ | $27.17 | $26.92 | $27.215 | $26.24 | 90,334 | 02-10-2020 |
$ | $26.53 | $26.09 | $26.92 | $25.34 | 110,269 | 02-07-2020 |
$ | $26.23 | $26.92 | $27.16 | $26.23 | 148,895 | 02-06-2020 |
$ | $25.43 | $26.07 | $26.26 | $25.22 | 66,310 | 02-05-2020 |
$ | $24.74 | $25.40 | $25.97 | $24.3921 | 209,573 | 02-04-2020 |
$ | $24.60 | $24.65 | $25.32 | $24.21 | 122,856 | 02-03-2020 |
$ | $25.00 | $24.69 | $25.26 | $24.25 | 104,168 | 01-31-2020 |
$ | $24.05 | $24.90 | $25.29 | $23.75 | 81,932 | 01-30-2020 |
$ | $23.50 | $23.90 | $24.74 | $23.50 | 54,855 | 01-29-2020 |
$ | $23.76 | $23.70 | $24.36 | $23.467 | 67,487 | 01-28-2020 |
$ | $24.42 | $23.59 | $25.75 | $23.26 | 124,639 | 01-27-2020 |
$ | $24.70 | $24.71 | $25.16 | $23.16 | 152,605 | 01-24-2020 |
$ | $23.40 | $24.50 | $25.94 | $23.24 | 167,790 | 01-23-2020 |
$ | $23.04 | $23.31 | $24.09 | $21.84 | 216,074 | 01-22-2020 |
$ | $21.44 | $22.94 | $23.31 | $21.00 | 377,535 | 01-21-2020 |
$ | $19.79 | $20.18 | $20.45 | $19.7101 | 121,991 | 01-20-2020 |
$ | $19.79 | $20.18 | $20.45 | $19.7101 | 120,240 | 01-17-2020 |
$ | $19.79 | $19.69 | $20.0019 | $19.67 | 234,423 | 01-16-2020 |
News, Short Squeeze, Breakout and More Instantly...
Akero Therapeutics Inc. Company Name:
AKRO Stock Symbol:
NYSE Market:
SOUTH SAN FRANCISCO, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease, today announced the appointment of Scott Gangloff as Chief Technology Officer. ...
LOS ANGELES, April 28, 2024 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class...
(NewsDirect) Investors are making a lot of money on obesity plays. Obesity is at epidemic proportions, so it's easy to see why obesity drugs including GLP-1 agonists have exploded in the marketplace. This class of drugs was originally designed to manage blood sugar levels in diabetics but was...